To determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high-risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).
A Phase 1 trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high-risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).
1. T-cell acute lymphoblastic leukemia in second or subsequent remission (≤ 5% blasts) 2. Relapsed T-cell lymphoblastic lymphoma with complete response after re-induction therapy
Protocol Number: 24-0339
More information available at ClinicalTrials.gov: NCT04972942
Principal Investigator